A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

  • STATUS
    Recruiting
  • End date
    Sep 12, 2022
  • participants needed
    428
  • sponsor
    Novartis Pharmaceuticals
Updated on 19 July 2021

Summary

Neovascular age-related macular degeneration (nAMD) is characterized by the presence of choroidal neovascularization (CNV). Choroidal neovascularization consists of abnormal blood vessels originating from the choroid and can lead to hemorrhage, fluid exudation, and fibrosis, resulting in photoreceptor damage and vision loss.

The safety and efficacy of brolucizumab has been demonstrated in 2 randomized, multicenter, double-masked, active controlled Phase 3 studies in nAMD patients (RTH258-C001 and RTH258-C002). Anatomical changes were evaluated in these studies using spectral domain optical coherence tomography (SD-OCT), which relied on indirect parameters for the diagnosis of active CNV. The OCT-angiography (OCT A) that directly visualize retinal circulation and image CNV and vascular diseases of the retina was not included in previous brolcuizumab studies.

This single-arm, open-label, multicenter study is being performed to evaluate the efficacy and safety of brolucizumab 6 mg in patients with nAMD.

OCT-A will be used in this study to assess the morphological response of patients to brolucizumab in terms of percentage change in CNV lesion area in the short term (i.e. at Week 12) and in the long term (i.e. at Week 48), as well as changes in other OCT-A features up to Week 48.

Approximately 428 adult patients will be screened and included in approximately 75 centers in France.

The maximum study duration for 1 patient is 48 weeks.

Patients will be required to attend 6 mandatory study visits: Screening/Baseline Visit (Day 1), Week 4, Week 8, Week 12, Week 16 and Week 48 visits. The timing of the interim visits between Week 16 and Week 48 will depend on the patient's injection regimen, i.e. every 8 weeks or every 12 weeks according to disease activity assessed by the investigator.

Details
Condition Neovascular Age Related Macular Degeneration
Treatment RTH258/Brolucizumab
Clinical Study IdentifierNCT04239027
SponsorNovartis Pharmaceuticals
Last Modified on19 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients must provide written informed consent before any study related procedures are performed
Patients must be 50 years of age or older at Screening/Baseline
Study eye
\. Active CNV lesions secondary to AMD that affect the central subfield
including retinal angiomatous proliferation (RAP) with a CNV component
confirmed by presence of active leakage from CNV seen by fluorescein
angiography and sequellae of CNV, e.g. pigment epithelial detachment (PED)
subretinal hemorrhage or sub-retinal pigment epithelium (sub-RPE) hemorrhage
blocked fluorescence, macular edema
\. Intra- and/or subretinal fluid affecting the central subfield of the study
eye at Screening/Baseline
\. BCVA between 83 and 23 letters, inclusive, in the study eye at
Screening/Baseline using early treatment diabetic retinopathy study (ETDRS) at
an initial testing distance of 4 meters

Exclusion Criteria

Ocular conditions
Any active intraocular or periocular infection or active intraocular inflammation (e.g. infectious conjunctivitis, keratitis, scleritis, endophthalmitis, infectious blepharitis) in either eye at Screening/Baseline
Presence of amblyopia, amaurosis or ocular disorders in the fellow eye with BCVA < 35 ETDRS letters at Screening (except when due to conditions whose surgery may improve visual acuity, e.g. cataract)
Study eye
\. Poor quality of OCT-A and SD-OCT images at Screening/Baseline
\. Atrophy or fibrosis involving the center of the fovea in the study eye, as
assessed by color fundus photography and fundus autofluorescence (FAF) at
Screening/Baseline
\. The total area of fibrosis or subretinal blood affecting the foveal center
point comprising 50% of the lesion area in the study eye at
Screening/Baseline
\. Concomitant conditions or ocular disorders in the study eye, including
retinal diseases other than nAMD, that, in the judgment of the investigator
could require medical or surgical intervention during the course of the study
to prevent or treat visual loss that might result from that condition, or that
limits the potential to gain visual acuity upon treatment with the
investigational product
\. Structural damage within 0.5 disc diameter of the center of the macula in
the study eye, e.g. vitreomacular traction, epiretinal membrane, retinal
pigment epithelium (RPE) rip/tear scar, laser burn, at the time of Screening
that in the investigator's opinion could preclude visual function improvement
with treatment
\. Current vitreous hemorrhage or history of vitreous hemorrhage in the study
eye within 4 weeks prior to Screening/Baseline
\. Uncontrolled glaucoma in the study eye defined as IOP > 25 mmHg on
medication or according to the investigator's judgment at Screening/Baseline
\. Aphakia and/or absence of the posterior capsule in the study eye at
Screening/Baseline
Ocular treatments (study eye)
\. Patient has received any approved or investigational treatment for nAMD
(other than vitamin supplements) in the study eye at any time
\. Intraocular or periocular use of corticosteroids in the study eye during
the 6-month period prior to Screening/Baseline
\. Previous penetrating keratoplasty or vitrectomy at any time prior to
Screening/Baseline
\. History or evidence of the following in the study eye within the 90-day
period prior to Screening/Baseline
Intraocular or refractive surgery
Previous panretinal photocoagulation
Previous submacular surgery, other surgical intervention or laser treatment for nAMD including photodynamic therapy (PDT)
Systemic conditions or treatments
\. End stage renal disease requiring dialysis or renal transplant
\. Systemic medications known to be toxic to the lens, retina or optic nerve
(e.g. deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines
and ethambutol) used during the 6-month period prior to Screening/Baseline
except temporary use for COVID-19 treatment
\. Participation in an investigational drug, biologic, or device study
within 30 days or the duration of 5 half-lives of the investigational product
(whichever is longer) prior to Screening/Baseline. Note: observational
clinical studies solely involving over-the-counter vitamins, supplements, or
diets are not exclusionary
\. Systemic anti-VEGF therapy at any time
\. Stroke or myocardial infarction in the 6-month period prior to
Screening/Baseline
\. Uncontrolled blood pressure defined as a systolic value 160 mmHg or
diastolic value 100 mmHg at Screening/Baseline. (In case there is an elevated
blood pressure measurement, it should be repeated after 20 minutes. If the
repeat measurement is elevated, then the patient is not eligible to be
enrolled into the study)
\. History of a medical condition (disease, metabolic dysfunction with
exception of type 1 or 2 diabetes mellitus, physical examination finding, or
clinical laboratory finding) that, in the judgment of the investigator, would
preclude scheduled study visits, completion of the study, or a safe
administration of investigational product
\. History of malignancy of any organ system (other than localized basal
cell carcinoma of the skin or in situ cervical cancer), treated or untreated
within the past 5 years, regardless of whether there is evidence of local
recurrence or metastases
\. History of hypersensitivity to any component of the test article, control
article, or clinically relevant sensitivity to fluorescein dye, as assessed by
the investigator
Other
\. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) pregnancy test. 25. Women of childbearing potential, defined as all women less than 1 year postmenopausal or less than 6 weeks since sterilization at Screening/Baseline Women are considered post-menopausal and not of childbearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks before taking study treatment. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of childbearing potential. 26. Patients mentioned in Articles L.1121-5 to L.1121-8 and L.1122-1-2 of the Code de Sant Publique (e.g. minors, protected adults, etc.)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note